UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hepatitis B

The Lancet (British edition), 2023-03, Vol.401 (10381), p.1039-1052

2023

Volltextzugriff (PDF)

Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B

Hepatology (Baltimore, Md.), 2018-08, Vol.68 (2), p.425-434

2018

Volltextzugriff (PDF)

Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients

Alimentary pharmacology & therapeutics, 2023-03, Vol.57 (5), p.577-578

2023

Volltextzugriff (PDF)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients—Authors' reply

Alimentary pharmacology & therapeutics, 2024-06, Vol.59 (11), p.1459-1461

2024

Volltextzugriff (PDF)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply

Alimentary pharmacology & therapeutics, 2024-06, Vol.59 (12), p.1618-1619

2024

Volltextzugriff (PDF)

Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection

Alimentary pharmacology & therapeutics, 2023-10, Vol.58 (7), p.731-732

2023

Volltextzugriff (PDF)

Letter: the probability of predicting HBV‐specific CD8+ cell response derived from HLA‐A2+ may not closely predict functional cure in Asian patients who stop nucleoside analogues

Alimentary pharmacology & therapeutics, 2022-10, Vol.56 (8), p.1310-1311

2022

Volltextzugriff (PDF)

Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival

Journal of clinical oncology, 2014-08, Vol.32 (22), p.2357-2364

2014

Volltextzugriff (PDF)

Editorial: is functional cure the only holy grail for treatment discontinuation in patients with HBeAg‐negative chronic hepatitis B?

Alimentary pharmacology & therapeutics, 2022-08, Vol.56 (3), p.544-545

2022

Volltextzugriff (PDF)

Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies

Liver international, 2022-03, Vol.42 (3), p.551-560

2022

Volltextzugriff (PDF)

Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals

Alimentary pharmacology & therapeutics, 2024-03, Vol.59 (6), p.762-773

2024

Volltextzugriff (PDF)

Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma

Annals of surgery, 2013-12, Vol.258 (6), p.1079-1086

2013

Volltextzugriff (PDF)

Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients

Hepatology (Baltimore, Md.), 2013-12, Vol.58 (6), p.1888-1896

2013

Volltextzugriff (PDF)

Letter: sPD‐1 as a predictor for HBsAg seroclearance—shed light on inactive carriers with chronic hepatitis B. Authors' reply

Alimentary pharmacology & therapeutics, 2022-04, Vol.55 (8), p.1057-1058

2022

Volltextzugriff (PDF)

Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients

Alimentary pharmacology & therapeutics, 2024-04, Vol.59 (8), p.993-1002

2024

Volltextzugriff (PDF)

Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients

Gut, 2020-10, Vol.69 (10), p.1898-1899

2020

Volltextzugriff (PDF)

Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients

Journal of viral hepatitis, 2019-08, Vol.26 (8), p.1019-1026

2019

Volltextzugriff (PDF)

Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy

Liver international, 2022-04, Vol.42 (4), p.945-946

2022

Volltextzugriff (PDF)

Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma (Review)

Oncology letters, 2019-11, Vol.18 (5), p.4377-4384

2019

Volltextzugriff (PDF)

Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy

The Lancet infectious diseases, 2021-07, Vol.21 (7), p.910-911

2021

Volltextzugriff (PDF)

APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients

Hepatology international, 2021-08, Vol.15 (4), p.833-851

2021

Volltextzugriff (PDF)

Efficacy of a multidimensional self-management intervention on low-education women with metabolic syndrome: a cluster randomized controlled trial

Scientific reports, 2023-06, Vol.13 (1), p.10358-10358, Article 10358

2023

Volltextzugriff (PDF)

A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off‐therapy relapse: An observational study

Journal of gastroenterology and hepatology, 2022-11, Vol.37 (11), p.2164-2172

2022

Volltextzugriff (PDF)

A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B

Liver international, 2023-01, Vol.43 (1), p.77-89

2023

Volltextzugriff (PDF)

The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B

Journal of viral hepatitis, 2021-03, Vol.28 (3), p.475-483

2021

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(211)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Englisch
(221)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(151)
Life Sciences & Biomedicine
(142)
Humans
(99)
Gastroenterology & Hepatology
(82)
Male
(60)
Female
(54)
Middle Aged
(47)
Hepatitis B
(40)
Hepatocellular Carcinoma
(38)
Aged
(37)
Adult
(32)
Antiviral Agents - Therapeutic Use
(31)
Hepatitis B, Chronic - Drug Therapy
(29)
Oncology
(29)
Retrospective Studies
(27)
Liver Cancer
(26)
Treatment Outcome
(25)
Hepatitis
(24)
Patients
(24)
Hepatitis B Virus - Genetics
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Hepatitis B

Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B

Editorial: considerations for expanding treatment in grey zone chronic hepatitis B patients

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients—Authors' reply

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply

Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection

Letter: the probability of predicting HBV‐specific CD8+ cell response derived from HLA‐A2+ may not closely predict functional cure in Asian patients who stop nucleoside analogues

Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival

Editorial: is functional cure the only holy grail for treatment discontinuation in patients with HBeAg‐negative chronic hepatitis B?

Off‐tenofovir hepatitis flares in HBeAg‐negative patients occur earlier, more frequent and severe than those off‐entecavir therapies

Higher end-of-treatment HBsAg levels is associated with later onset but not severe relapse in HBeAg-negative chronic hepatitis B patients stopping antivirals

Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma

Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients

Letter: sPD‐1 as a predictor for HBsAg seroclearance—shed light on inactive carriers with chronic hepatitis B. Authors' reply

Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients

Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients

Off‐therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg‐negative patients

Hepatocellular carcinoma and HBsAg loss after cessation of antiviral therapy

Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma (Review)

Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy

APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients

Efficacy of a multidimensional self-management intervention on low-education women with metabolic syndrome: a cluster randomized controlled trial

A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off‐therapy relapse: An observational study

A phase 2, open‐label, randomized, multiple‐dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B

The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B

Suchergebnisse filtern